Polypharmacy associated with medical tourism: a critique on drug therapy
- 229 Downloads
Medical tourism is the practice of patients seeking health care services from an area outside their home country. In recent years, medical tourism has rapidly grown for the following reasons: (a) inadequate access to health care services at home country; (b) the treatment is not covered by health insurance providers; (c) the service is available at a much lower cost elsewhere; and (d) long waiting period to get access to care as a result of overburden on public health-care system at home country . Complicated urgent surgeries and elective procedures are the most frequently sought procedures by patients as medical tourists .
Polypharmacy is the prescription, administration, or use of more medications than are clinically warranted . Polypharmacy has been shown to predispose patients to drug-drug interactions, adverse drug reactions, and poor patient compliance .
We present a case of polypharmacy associated with medical tourism in a middle-aged Bahraini who sought...
KeywordsMetformin Tramadol Rosiglitazone Fenofibrate Pregabalin
We are grateful to the patient who has given consent for publication of this report. We acknowledge Mr. Mohd Ghali Rashid (Reference Librarian) for information retrieval, and Ms. Radha Raghavan for assistance in preparing this manuscript.
Conflicts of interests
There is no conflict of interest to declare.
- 1.Pennings G. Ethics without boundaries: medical tourism. In: Ashcroft RE, Dawson A, Draper H, McMillan JR, editors. Principles of health care ethics, 2nd edn. West Sussex, England: Wiley; 2007. Print ISBN: 978 047002 713 4; online ISBN 978 047051 054 4.Google Scholar
- 2.Horowitz MD, Rosensweig J, Jones CA. Medical trourism: globalization of the healthcare marketplace. Med Gen Med. 2007;9:33.Google Scholar
- 6.British National Formulary (BNF)-55: March 2008. BMJ Group and RPS Publishing 2008. Print ISBN: 978 085369 776 3.Google Scholar
- 7.Martindale. The complete drug reference. Thirty-third edition (ed) Sweetman SC. London: Chicago Pharmaceutical Press; 2002. Print ISBN 0 85369 499 0.Google Scholar
- 8.Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 18: CD003639.Google Scholar
- 10.Starner CI, Schafer JA, Heaton AH, Gleason PP. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk warning events. J Manag Care Pharm. 2007;14:523–31.Google Scholar
- 11.American Diabetes Association. Position statement. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004; 27 (suppl 1): S68–71.Google Scholar
- 13.Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on pharmacokinetics and drug interactions. Circulation. 2004;109(23 Suppl 1):11150–7.Google Scholar
- 15.American Diabetes Association. Position statement. Diabetic nephropathy. Diabetes Care. 2002; 25(Suppl 1): S85–9.Google Scholar